CB1 Receptors: Function, Location, and Effects

CB1 receptors are the primary molecular target through which cannabis produces its mood-altering, pain-relieving, and appetite-stimulating effects. They are a type of protein embedded in cell membranes, most densely concentrated in the brain but also scattered across peripheral organs, and they respond to both the body’s own signaling molecules and to plant-derived or synthetic cannabinoids. What makes CB1 receptors fascinating, and worth understanding beyond the cannabis connection, is how deeply they are woven into basic neural housekeeping: they fine-tune the release of other chemical messengers, shape how memories form and dissolve, regulate energy balance, and even influence heart and immune function.

What CB1 Receptors Actually Do at the Cellular Level

CB1 belongs to a large family of cell-surface proteins called G protein-coupled receptors. When a molecule binds to CB1, the receptor changes shape and activates a partner protein inside the cell, most often one that dials down production of a key signaling molecule called cyclic AMP. That single event sets off a cascade: certain calcium channels close, certain potassium channels open, and enzymes involved in cell growth and survival get switched on or off.¹ The net result, in a neuron, is that the cell becomes less excitable and less likely to release its chemical messengers into the synapse.

Structural work has revealed exactly how this happens at the atomic level. A 2019 study captured the three-dimensional shape of CB1 locked in its active state while bound to both an agonist molecule and its G protein partner, showing how the receptor’s internal pocket widens to flip the G protein into an active conformation.² CB1 primarily couples with one type of G protein, but it can also engage alternative types, which partly explains why its downstream effects vary between tissues and conditions.³

Where CB1 Receptors Are Found

CB1 is the most abundant G protein-coupled receptor in the mammalian brain. The highest densities sit in regions you would expect given what cannabis does to people: the hippocampus (learning and memory), the basal ganglia and cerebellum (movement coordination), the prefrontal cortex (decision-making and planning), and the amygdala (fear and emotional processing). The hypothalamus, which orchestrates hunger and energy expenditure, also expresses them heavily.⁴ The brainstem and spinal cord have lower but functionally significant levels, especially in pain-processing circuits.⁵

Outside the brain, CB1 shows up in the liver, fat tissue, the gastrointestinal tract, the heart, and the vasculature. In the liver, for example, CB1 activation on hepatocytes influences fat metabolism and insulin signaling, and its role shifts depending on whether the liver is healthy or already loaded with excess fat.⁶ In the immune system, CB1 expression is lower than its sibling receptor CB2, but still high enough to directly modulate the behavior of certain immune cells.⁷

The Retrograde Messenger System

Most chemical signaling in the brain runs in one direction: a presynaptic neuron releases a transmitter, and the postsynaptic neuron receives it. CB1 receptors work in reverse. When a postsynaptic neuron is strongly activated, it synthesizes endocannabinoids on demand from fats in its own membrane. The two main endocannabinoids are anandamide and 2-arachidonoylglycerol (2-AG). 2-AG is produced from membrane lipids through a two-step enzymatic process and is the more abundant of the two in brain tissue.⁸ Anandamide has its own distinct synthesis route, arising from a different class of membrane lipids.⁹

These endocannabinoids travel backward across the synapse and land on CB1 receptors sitting on the presynaptic terminal. Once CB1 is activated there, it suppresses calcium channels that are needed for vesicle release, effectively telling the presynaptic neuron to ease off. In the hippocampus, this process specifically targets certain types of presynaptic terminals, and the suppression of calcium influx through those channels is mediated directly by G proteins.¹⁰ In the striatum, a brain region involved in movement and reward, CB1 activation reduces the release of glutamate, the brain’s main excitatory transmitter, from incoming nerve fibers.¹¹

This retrograde braking system is what gives the endocannabinoid system its distinctive character. Rather than broadcasting a signal forward like most neurotransmitters, it acts as a feedback dial, letting a receiving neuron control how much stimulation it gets. The system is self-limiting by design: endocannabinoids are made on demand, act locally, and are quickly broken down by enzymes. At least eight different enzymes participate in degrading 2-AG alone, some of which convert it into other bioactive molecules rather than simply destroying it.⁸

CB1 Receptors Inside the Cell

For a long time, researchers assumed CB1 mattered only when it sat on the outer cell membrane. That assumption was overturned when a team discovered functional CB1 receptors on the outer membranes of mitochondria, the organelles that produce most of a cell’s energy. When these mitochondrial CB1 receptors are activated, they reduce the activity of a key enzyme complex in the energy-production chain, lowering the cell’s overall respiratory output. Both externally applied cannabinoids and endocannabinoids produced inside the neuron triggered this effect.¹² The finding added a whole new dimension to how cannabinoids affect the brain: beyond just tweaking synaptic transmission, they can throttle the energy supply of individual neurons.

Astrocytes and the Memory Problem

Neurons get most of the attention, but CB1 receptors on astrocytes, the star-shaped support cells that outnumber neurons in many brain regions, turn out to be surprisingly important. Astrocytes use CB1 signaling to regulate their calcium activity, their release of signaling molecules, their metabolic cooperation with nearby neurons, and their inflammatory responses.¹³ CB1 on astrocytes has emerged as a critical player in how these cells supply energy to neurons and modulate synaptic activity.¹⁴

A landmark study using mice engineered to lack CB1 only in specific cell types revealed something unexpected about the short-term memory impairment that THC produces. Deleting CB1 from the brain’s excitatory or inhibitory neurons did not prevent the memory deficit. Deleting it from astrocytes did. THC acting on astroglial CB1 receptors induced a form of long-term synaptic weakening at hippocampal connections, and the same mechanism drove the impairment of spatial working memory.¹⁵ The practical meaning is that the “forgetfulness” people associate with cannabis use is not simply a matter of neurons being quieted; it involves astrocytes reshaping the strength of connections between neurons.

Appetite, Hunger, and Metabolic Regulation

The “munchies” have a clear molecular basis. CB1 signaling in the hypothalamus promotes appetite and stimulates feeding, while blocking CB1 suppresses hunger.¹⁶ The hypothalamus integrates signals about the body’s energy stores and caloric needs, and CB1 sits at several nodes of that integration. This is why both THC and the body’s own endocannabinoids, particularly anandamide, can shift eating behavior and energy expenditure.⁴

In obesity, the endocannabinoid system becomes chronically overactive, contributing to a cycle of excess caloric intake and metabolic dysfunction. Researchers have investigated CB1 blockade as a pharmacological approach to treating obesity.¹⁷ The drug rimonabant, a CB1 blocker, was briefly marketed in Europe for weight loss but withdrawn because blocking CB1 throughout the brain also produced serious psychiatric side effects, including depression and suicidal ideation. That experience highlighted a core challenge with CB1 as a drug target: the receptor does so many things in so many places that shutting it down globally comes with steep costs.

CB1 in the Liver and Peripheral Metabolism

The metabolic story does not stop at the brain. In the liver, CB1 receptors on hepatocytes directly regulate fat processing and insulin signaling. In lean, healthy animals, hepatocyte CB1 actually inhibits fat uptake and promotes fat burning through one signaling pathway. But in obesity, the receptor’s coupling switches: it begins routing through a different G protein, and the downstream effect reverses, promoting fat accumulation and contributing to fatty liver disease.⁶ Separately, activating CB1 on hepatocytes in the context of a high-fat diet induces a stress response inside the cell that interferes with insulin’s ability to regulate blood sugar, contributing to insulin resistance.¹⁸

This dual personality of hepatic CB1, helpful in the lean state, harmful in the obese state, is one of the more intriguing twists in the field. It suggests that the metabolic problems associated with an overactive endocannabinoid system are not simply “too much CB1 activation” but a qualitative shift in what that activation does.

Pain Processing

CB1 receptors modulate pain at multiple levels of the nervous system. In animal models, analgesic activity during chronic pain appears to involve CB1 in the spinal cord, brainstem, peripheral sensory neurons, and immune cells, not just the brain regions responsible for the subjective “high.”⁵ In the spinal cord specifically, selective activation of CB1 reduced the firing of pain-sensing nerve fibers in a dose-dependent fashion, and a CB1-blocking drug reversed the effect, confirming that the suppression ran through CB1.¹⁹

This multi-site involvement is why cannabinoid-based pain relief has generated so much interest and so much frustration. The analgesic effects are real but come bundled with psychoactive and sedative effects mediated by the same receptor in the brain. Separating the two, getting pain relief without the high, remains one of the central problems in cannabinoid pharmacology.

Emotion, Fear, and Stress

CB1 receptors on inhibitory and excitatory neurons play complementary roles in emotional regulation. On excitatory neurons, CB1 activation dampens glutamate release, while on inhibitory neurons, it dampens GABA release. The interplay lets the endocannabinoid system act as a kind of emotional thermostat. Stressful or rewarding experiences can actually change how many CB1 receptors are present on inhibitory neurons, adjusting the system’s sensitivity over time.²⁰

In fear-memory research, CB1 signaling is involved in two opposing processes: reconsolidation (the restabilization of a fear memory after it is recalled) and extinction (the gradual fading of a fear response when the threat no longer appears). Endocannabinoid activation weakens reconsolidation, while intact CB1 signaling is required for proper extinction to occur.²⁰ This has implications for anxiety disorders and PTSD, where both processes are disrupted.

Cardiovascular Effects

CB1 activation in the cardiovascular system generally lowers blood pressure, though the mechanism depends on the compound involved. In anesthetized rats, a potent synthetic CB1 agonist reduced mean blood pressure substantially, primarily by decreasing cardiac output without changing overall vascular resistance. The endocannabinoid anandamide, by contrast, lowered blood pressure by reducing vascular resistance while leaving cardiac output untouched. Both compounds caused the most pronounced blood vessel relaxation in the coronary and cerebral circulations.²¹

In spontaneously hypertensive rats, endocannabinoids acting through CB1 appear to exert a tonic blood-pressure-lowering effect. Blocking CB1 in these animals raised blood pressure further, while boosting endocannabinoid levels brought blood pressure down toward normal.²² Whether this translates meaningfully to human hypertension management remains an open and complicated question.

Immune Modulation and Neuroinflammation

Although CB2 is considered the primary cannabinoid receptor of the immune system, CB1 contributes meaningfully to immune regulation. Studies have documented direct effects of CB1 activation on T cells and innate immune cells, and indirect CB1-dependent suppression of inflammation has been demonstrated in the nervous system. The mechanism by which cannabinoids reduce neuroinflammation through CB1 appears to combine immune suppression with direct neuroprotection.⁷ More broadly, the endocannabinoid system modulates the cytokine network, induces programmed cell death in certain immune cells, and tones down both innate and adaptive immune responses.²³

Tolerance and Why It Develops

Anyone who uses cannabis regularly notices that the same dose produces weaker effects over time. At the molecular level, this reflects two things: CB1 receptors get pulled off the cell surface (downregulation), and the remaining receptors become less responsive to activation (desensitization). Both processes are regulated in part by a protein called beta-arrestin-2, which tags activated CB1 for removal. In mice lacking this protein, chronic THC treatment caused significantly less CB1 downregulation in the spinal cord compared to normal mice, and tolerance to THC’s pain-relieving effects was reduced.²⁴ The tolerance process varies by brain region, which is why different effects of cannabis (pain relief, mood changes, motor impairment) develop tolerance at different rates.

Synthetic Cannabinoids and the Danger of Full Agonism

THC is a partial agonist at CB1, meaning it activates the receptor but only pushes it partway toward its maximum response. Many synthetic cannabinoid receptor agonists, the compounds found in products marketed as “spice” or “K2,” are full agonists with far greater potency and efficacy. Laboratory measurements show that THC’s ability to activate CB1 signaling is roughly 80 times less than a standard reference agonist and up to 260 times less than some of the most potent synthetics.²⁵ This enormous difference in how hard they push the receptor helps explain why synthetic cannabinoids produce seizures, psychosis, and cardiac events that cannabis itself rarely causes.²⁶ Calling them “synthetic cannabis” is genuinely misleading; pharmacologically, they are a different class of drug.

Allosteric Modulation and New Drug Strategies

The rimonabant debacle taught drug developers that simply blocking CB1 everywhere is too blunt an approach. One promising alternative is allosteric modulation, where a drug binds to a different site on the receptor rather than the main pocket where endocannabinoids land. An allosteric modulator can fine-tune CB1 activity without fully switching it on or off, and can potentially be made selective for specific signaling pathways or specific tissues.²⁷ First-generation allosteric modulators of CB1 have been identified and characterized, and the hope is that they will allow the beneficial effects of CB1 manipulation, metabolic improvements, pain relief, anxiety reduction, without the full constellation of side effects that come from a sledgehammer approach.

CB1 in Brain Development

CB1 receptors and their endocannabinoid ligands appear early in fetal brain development, well before many other receptor systems are fully online. During this period, CB1 is abundantly expressed in brain regions involved in guiding growing nerve fibers to their correct targets. Research has found CB1 colocalized with proteins that govern axon elongation and pathfinding in the developing forebrain, supporting the idea that endocannabinoid signaling plays a role in wiring the brain during gestation.²⁸ This developmental role is one of the main biological reasons for concern about prenatal cannabis exposure: flooding the fetal brain with THC during a period when CB1 is helping to lay down neural architecture could disrupt normal connectivity.

Evolutionary Origins

CB1-type receptors are not universal across animals. Genes encoding CB1 have been identified in fish, amphibians, birds, and mammals, suggesting the receptor is present across vertebrates. However, the genomes of fruit flies and the roundworm C. elegans, two of the best-studied invertebrates, lack CB1 genes entirely.²⁹ The best current evidence places the origin of CB1/CB2-type receptors in an ancestor shared by all chordates, the broad group that includes vertebrates plus animals like sea squirts. In the sea squirt Ciona intestinalis, a CB1/CB2-type receptor has been found specifically localized to axons, hinting that the cannabinoid system’s role in regulating nerve signaling is ancient.³⁰

Interestingly, the enzymes that make and break down endocannabinoids are far more widespread than the receptors themselves, appearing throughout the animal kingdom. Evolutionary analysis suggests that cannabinoid receptors first coevolved with a lipid-based ligand similar to 2-AG, and the ability to respond to molecules like anandamide developed later.³¹ The practical takeaway for anyone interested in animal models: endocannabinoid signaling in invertebrates, which is sometimes invoked in popular science, probably does not rely on CB1-type receptors at all, and findings from insects or worms should be interpreted cautiously when extrapolated to mammals.